Equity Research, Broker Reports, and media content on VISTIN PHARMA AS

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about VISTIN PHARMA AS
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
Login

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on VISTIN PHARMA AS. We currently have 0 research reports from 0 professional analysts.

Open
N/A
Volume
N/A
Range Today
N/A
52 Week
0.00/0.00
Market Cap
0m
Enterprise Value
n/am
Pension Liability
# Shares
0m
Latest PE (hist)
Div Yield

Latest News/RNS

(more news)
Date Source Announcement
26Apr18 06:01 GNW Vistin Pharma ASA : Delivers 22% revenue growth in first quarter 2018
22Mar18 15:36 GNW Vistin Pharma ASA : UPDATE ON THE ENERGY TRADING BUSINESS
16Mar18 09:47 GNW Vistin Pharma ASA : Torbjørn Kjus joins Vistin to develop new business area
27Feb18 06:00 GNW Vistin Pharma ASA : Fourth quarter 2017 results
09Oct17 13:33 GNW Vistin Pharma ASA : Proposal for Extraordinary Dividend
02Oct17 09:28 GNW Vistin Pharma ASA : Sale of Opioids and CMO business completed
31Aug17 06:00 GNW Vistin Pharma ASA : Second quarter 2017 results - continuing strong demand for metformin
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    VISTIN PHARMA AS

  • Providers covering

    VISTIN PHARMA AS

  • 17 Aug 18

Hutchison China MediTech - Establishing a global operational presence

Highlights from Hutchison China MediTech’s (HCM) H118 results relate to the substantial pipeline-related newsflow expected in 2018/19, the recent expansion of its US and international operations (which will enable HCM to execute its international R&D and commercialisation strategies) plus strong operational and financial performance by the China commercial platform division. Fruquintinib (third-line CRC) remains on track to launch in China by year end (approval decision expected by the CNDA in the next few months). Encouraging Phase II data so far on savolitinib (first-line NSCLC exon14m/deletion) could lead to accelerated approval in China, contingent on final data (expected in 2020) being consistent with data to date. We value HCM at $6.4bn or £73.3/share.

Companies: Hutchison China Meditech
  • 20 Aug 18

Cenkos: Kromek Group Plc - Scaling up production

A spate of contract newsflow is increasing revenue visibility over this year. Some new and incremental addressable markets are being discovered for Kromek's CZT based detection equipment. The footprint of the business is steadily increasing and its size will be enhanced materially as the US manufacturing facility ramps up this fiscal year.

Companies: Kromek Group
  • 01 Aug 18

The Monthly

Hardman & Co’s analysts have direct experience of uncovering accounting frauds. In this article, Steve Clapham outlines why we might see a surge in them over the next few years. He is engaged by institutions to teach their fund managers and analysts how to identify risks brought about by such frauds. Hardman & Co is pleased to offer this service to private investors.

Companies: OPM AVO AGY APH ARBB AVCT BUR CMH CLIG COS DNL EVG GDR INL KOOV MCL MUR NSF OXB PHP RE/ REDX SCLP SCE SIXH TRX TON VAL W7L

  • 20 Aug 18

Increasingly more confident

Hot on the heels of winning up to $3.3m of home security contracts in late July with the US government, Kromek today said that it had secured two more significant orders. Both within healthcare and together worth >$1m.

Companies: Kromek Group
  • 18 Jul 18

Quarterly Research Outlook

In Q2, UK equities regained some of their poise after the draw down in Q1, although uncertainty around Brexit continued to grab the headlines. On the back of this, investor concern about the UK economy has been understandable in recent months given a number of negative data points. However, we see reasons for optimism for UK Plc with wage growth supporting an improving outlook for the consumer and business investment holding up. That said, continuing UK political disruption clearly remains a risk going forward.

Companies: AMER EMR HMI JOG PDG ABBY AMS AVON BLVN PIER CGS CALL CSRT TIDE DTG DEMG ELM EMR FPM FPO GTLY GENL GOR GEEC HDY HMI HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD JOG LAM MACF MKLW NAH OXIG PCA PKG CAKE PDG RBW REDD RSW RNO RKH ROR SUS SCPA SHG SIV TRAK TRI VTC ZTF

  • 07 Aug 18

Markets still range bound

Last week, the MPC increased the Bank Rate by 0.25% to 0.75% only the second increase since financial crisis. The market reaction was muted. Sentiment continues to be impacted by continuing tariff and trade war concerns, combined with ongoing Brexit uncertainty. As Table 1 shows, the major indices have fallen over the last fortnight. Markets continue to be range bound, partly due to the holiday period. In Share News & Views, we comment on APC Technology*, Braemar*, Burford, Clipper, FireAngel Safety* GetBusy* Goodwin*, Hargreaves, Live Company*, NWF, Vitesse Media* and Warpaint*

Companies: AOR APC BMS CRPR DMTR ECSC ESC EUSP FDM GETB LSAI PCF SNX TCN VIS W7L

  • 16 Aug 18

Building for growth

Ergomed’s strategy is to become a global leader in pharmacovigilance and orphan drug development services by 2020. This refocusing of the business, communicated earlier in the year, moves Ergomed away from its reliance on the risk/reward profile of development deals and will ultimately result in a much better, more visible, and cash-generating story.

Companies: Ergomed
  • 20 Aug 18

Interim trading update and HUP progress

The transition of LiDCO from a razor/razor blade model into a SaaS operating model, selling High Usage Programme (HUP) hemodynamic monitors, continues, albeit the sales cycle remains a long one. Three new US HUP wins announced today (21 monitors) takes H1 customer wins to five and seven in total, with scope for these hospitals to build their HUP installed base given their sizes. First half revenues are 8% lower than last year, affected by lower third-party revenues and less capital sales as customers look to the SaaS HUP model; however, encouragingly, recurring revenues rose 11%, with US up 59%. The outlook is for a much stronger second half with revenue growth dependent on timing of new HUP customers and the quantum of capital sales in the UK. We have reduced revenues by c.£1m and PBT by c.£0.2m, but given our unchanged year-end cash and future recurring revenues, target price remains 14p, underpinned by a 10-year DCF of 21p.

Companies: Lidco Group
  • 28 Jun 18

Momentum screen refresh + 7 highlighted stocks

We report on the performance of our momentum style screen since the last refresh three months ago and present the 25 new constituents. The screen underperformed small-cap and microcap indices modestly, though our previous focus stocks did significantly better. While momentum (as we express it) has outperformed smallcap significantly since inception of the screen in July 2016, this has arisen in shorter periods and appears to only coincide with a steadily rising small-cap index. We therefore consider this style screen to have limited predictive capability. We highlight seven stocks, which we think are interesting.

Companies: BMY EKT KEYS LGT MACF VER WYG

  • 24 Jul 18

Strong interims drive full year upgrades

Bioquell has reported a strong set of interim results, with reported revenues +9% to £15.7m. Excluding Defence sales and the disposed-of Airflow business, like-for-like revenues increased by 15% on a constant currency basis. In light of the strong H1 showing and positive commentary over the outlook, we upgrade our EPS forecasts by 10% this year and 13% in FY19, the fourth double digit upgrades we have made in the last 12m. The growth opportunity is by no means exhausted however and we see the FY19 rating of under 10x EV/EBITDA as extremely undemanding.

Companies: Bioquell
  • 20 Aug 18

Hutchison China MediTech - Establishing a global operational presence

Highlights from Hutchison China MediTech’s (HCM) H118 results relate to the substantial pipeline-related newsflow expected in 2018/19, the recent expansion of its US and international operations (which will enable HCM to execute its international R&D and commercialization strategies) plus strong operational and financial performance by the China commercial platform division. Fruquintinib (third-line CRC) remains on track to launch in China by year end (approval decision expected by the CNDA in the next few months). Encouraging Phase II data so far on savolitinib (first-line NSCLC exon14m/deletion) could lead to accelerated approval in China, contingent on final data (expected in 2020) being consistent with data to date. We value HCM at $6.4bn.

Companies: Hutchison China Meditech
  • 24 Jan 18

Poised for Growth Inflection

Fusion Antibodies is a highly specialised CRO (contract research organisation) operating in the field of monoclonal antibody (mAb) production and engineering. The global CRO market is estimated to be worth over $30bn growing at a CAGR of c 12% pa to 2020 . The Company is well established and differentiated by means of its expertise, technology and the quality of its partnerships. The existing customer base includes top five ‘big pharma’, and is globally spread. Fusion has a proven record of revenue growth (up by 220% from FY15-17) with a FY17 reported EBITDA margin of 8%. The Company is entering a period of expansion targeting geographic growth and investing in greater capacity to meet sustained demand for its services. We forecast a sales CAGR of 67% over the period FY17-20 with EBITDA margin rising to 26% in FY20.

Companies: Fusion Antibodies
  • 05 Mar 18

Growth story on track

Growth story on track Fusion Antibodies, a specialised Contract Research Organisation operating in the field of monoclonal antibody engineering and production, has provided an update on trading for the year ending 31 March 2018. It reports that FY18 revenues are expected to grow sizeably by at least 40% from £1.9m in FY17. This is slightly below expectations, due to the temporary impact of management time dedicated to IPO preparations during FY18. Nevertheless, delivery of higher margin services in H2 helped to largely offset this impact on profits and growth for FY19 and beyond remains on track.

Companies: Fusion Antibodies
  • 16 Aug 18

Full Year results

Resetting the growth trajectory Fusion Antibodies (FAB) is a specialised Contract Research Organisation (CRO) operating in the field of monoclonal antibody engineering and production. The company has reported a 41% increase in FY18 revenues from £1.9m to £2.7m, in line with our forecasts, following its AIM listing in December. Growth was driven by the firm underlying demand in the base CRO outsourcing market and by achieving geographic expansion and driven by provision of high margin, antibody humanisation and stable cell line development services.

Companies: Fusion Antibodies
  • 09 Jan 18

Ongoing strength prompts further upgrades

A further strong trading update for FY17 has prompted further double digit PBT/EPS upgrades this morning, adding to the strong forecast momentum experienced in recent months. The core Biodecon activities are benefitting from the improved commercial focus and this is now being seen strongly in the reported financials, which are beginning to look increasingly attractive in terms of growth, margins and cash generation. Net Cash reached £14.5m at the year end, increasing the scope for some kind of further returns to shareholders. We see intrinsic value of 300p+, with further upside scope on growth, forecast outperformance and possible cash returns.

Companies: Bioquell